JP2018529635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529635A5 JP2018529635A5 JP2018501182A JP2018501182A JP2018529635A5 JP 2018529635 A5 JP2018529635 A5 JP 2018529635A5 JP 2018501182 A JP2018501182 A JP 2018501182A JP 2018501182 A JP2018501182 A JP 2018501182A JP 2018529635 A5 JP2018529635 A5 JP 2018529635A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 214
- 239000012634 fragment Substances 0.000 claims description 202
- 239000000427 antigen Substances 0.000 claims description 201
- 102000036639 antigens Human genes 0.000 claims description 201
- 108091007433 antigens Proteins 0.000 claims description 201
- 102100037632 Progranulin Human genes 0.000 claims description 26
- 101710114165 Progranulin Proteins 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 8
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100032889 Sortilin Human genes 0.000 description 20
- 108010014657 sortilin Proteins 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 101000868139 Homo sapiens Sortilin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101150014554 TARDBP gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021151783A JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512215.3A GB201512215D0 (en) | 2015-07-13 | 2015-07-13 | Agents,uses and methods |
| GB1512215.3 | 2015-07-13 | ||
| PCT/EP2016/066516 WO2017009327A1 (en) | 2015-07-13 | 2016-07-12 | Antibodies that bind to sortilin and inhibit the binding of progranulin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021151783A Division JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529635A JP2018529635A (ja) | 2018-10-11 |
| JP2018529635A5 true JP2018529635A5 (enExample) | 2019-08-15 |
| JP6979397B2 JP6979397B2 (ja) | 2021-12-15 |
Family
ID=54013862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501182A Active JP6979397B2 (ja) | 2015-07-13 | 2016-07-12 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
| JP2021151783A Pending JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021151783A Pending JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Country Status (35)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
| LT3280441T (lt) | 2015-04-07 | 2021-11-25 | Alector Llc | Anti-sortilino antikūnai ir jų naudojimo būdai |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10894833B2 (en) * | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| EP3666281A1 (en) * | 2018-12-14 | 2020-06-17 | Insusense ApS | Compositions comprising sortilin-1 |
| IL293994A (en) * | 2019-12-23 | 2022-08-01 | Denali Therapeutics Inc | Progranulin variants, compositions comprising same and uses thereof |
| CA3183994A1 (en) * | 2020-06-24 | 2021-12-30 | Philip James Dolan Iii | Antibodies recognizing sortilin |
| CN119403786A (zh) | 2022-06-23 | 2025-02-07 | 德罗普尼尔生物有限公司 | 选择性诱导细胞外靶标在溶酶体中降解的双功能分子 |
| CN118496354A (zh) * | 2023-02-15 | 2024-08-16 | 三优生物医药(上海)有限公司 | 包含共同轻链的抗体库、其制备方法及其用途 |
| WO2025031098A1 (zh) * | 2023-08-09 | 2025-02-13 | 瑞诺元(苏州)生物科技有限公司 | 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用 |
| WO2025132764A1 (en) * | 2023-12-21 | 2025-06-26 | Amylonix Ab | A sortilin-binding polypeptide |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| ATE545429T1 (de) | 2002-12-20 | 2012-03-15 | Lundbeck & Co As H | Modulation der neurotrophinaktivität;screeningsverfahren |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
| EP3225251B1 (en) * | 2006-12-21 | 2020-02-12 | H. Lundbeck A/S | Modulation of activity of proneurotrophins |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| CN102131826B (zh) | 2008-04-27 | 2014-07-02 | H.隆德贝克有限公司 | 人类分拣蛋白的晶体结构及其用于鉴定分拣蛋白的配体的用途 |
| EP2293667A4 (en) | 2008-05-27 | 2012-07-18 | Kyowa Hakko Kirin Co Ltd | INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS |
| US20120039865A1 (en) | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| US8703125B2 (en) | 2008-12-19 | 2014-04-22 | H. Lundbeck A/S | Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders |
| RU2536232C2 (ru) * | 2011-07-01 | 2014-12-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
| JP6239635B2 (ja) | 2012-11-02 | 2017-11-29 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 血管石灰化の誘導因子であるソルチリン１ |
| LT3280441T (lt) | 2015-04-07 | 2021-11-25 | Alector Llc | Anti-sortilino antikūnai ir jų naudojimo būdai |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
-
2015
- 2015-07-13 GB GBGB1512215.3A patent/GB201512215D0/en not_active Ceased
-
2016
- 2016-07-11 JO JOP/2016/0141A patent/JO3710B1/ar active
- 2016-07-12 TW TW105121903A patent/TWI760305B/zh not_active IP Right Cessation
- 2016-07-12 RU RU2018100824A patent/RU2735639C2/ru active
- 2016-07-12 AR ARP160102109A patent/AR105335A1/es not_active Application Discontinuation
- 2016-07-12 CR CR20180002A patent/CR20180002A/es unknown
- 2016-07-12 CN CN202210124752.3A patent/CN114478775A/zh active Pending
- 2016-07-12 EP EP16739087.1A patent/EP3322726B1/en active Active
- 2016-07-12 ES ES16739087T patent/ES3024469T3/es active Active
- 2016-07-12 UA UAA201800574A patent/UA125136C2/uk unknown
- 2016-07-12 PL PL16739087.1T patent/PL3322726T3/pl unknown
- 2016-07-12 HU HUE16739087A patent/HUE071424T2/hu unknown
- 2016-07-12 CN CN202210124751.9A patent/CN114478774A/zh active Pending
- 2016-07-12 KR KR1020187001192A patent/KR102778576B1/ko active Active
- 2016-07-12 US US15/743,549 patent/US10479835B2/en active Active
- 2016-07-12 US US15/207,880 patent/US10428147B2/en active Active
- 2016-07-12 TN TNP/2017/000534A patent/TN2017000534A1/en unknown
- 2016-07-12 HR HRP20250602TT patent/HRP20250602T1/hr unknown
- 2016-07-12 BR BR112018000771-4A patent/BR112018000771A2/pt not_active IP Right Cessation
- 2016-07-12 WO PCT/EP2016/066516 patent/WO2017009327A1/en not_active Ceased
- 2016-07-12 MX MX2018000506A patent/MX2018000506A/es unknown
- 2016-07-12 PE PE2018000064A patent/PE20181014A1/es unknown
- 2016-07-12 RS RS20250507A patent/RS66856B1/sr unknown
- 2016-07-12 EA EA201890038A patent/EA201890038A1/ru unknown
- 2016-07-12 JP JP2018501182A patent/JP6979397B2/ja active Active
- 2016-07-12 CA CA2989739A patent/CA2989739A1/en active Pending
- 2016-07-12 AU AU2016292980A patent/AU2016292980B2/en active Active
- 2016-07-12 MA MA42440A patent/MA42440B1/fr unknown
- 2016-07-12 CN CN201680040476.5A patent/CN107849135A/zh active Pending
-
2017
- 2017-12-18 CO CONC2017/0012988A patent/CO2017012988A2/es unknown
- 2017-12-18 ZA ZA2017/08613A patent/ZA201708613B/en unknown
- 2017-12-22 IL IL256503A patent/IL256503B/en unknown
-
2018
- 2018-01-11 SV SV2018005613A patent/SV2018005613A/es unknown
- 2018-01-11 DO DO2018000014A patent/DOP2018000014A/es unknown
- 2018-01-11 NI NI201800007A patent/NI201800007A/es unknown
- 2018-01-11 CL CL2018000092A patent/CL2018000092A1/es unknown
- 2018-01-11 PH PH12018500100A patent/PH12018500100A1/en unknown
- 2018-01-12 EC ECIEPI20182725A patent/ECSP18002725A/es unknown
-
2019
- 2019-07-24 US US16/521,279 patent/US10889650B2/en active Active
-
2020
- 2020-09-24 CL CL2020002468A patent/CL2020002468A1/es unknown
- 2020-11-13 US US17/097,457 patent/US11548950B2/en active Active
-
2021
- 2021-09-17 JP JP2021151783A patent/JP2022003058A/ja active Pending
-
2022
- 2022-11-18 US US18/057,104 patent/US12331123B2/en active Active
-
2025
- 2025-05-16 US US19/210,142 patent/US20250277040A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529635A5 (enExample) | ||
| US11859000B2 (en) | Anti-CCR8 antibodies and uses thereof | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| KR102365871B1 (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
| AU2012347972B2 (en) | PDGF receptor beta binding polypeptides | |
| JP7352973B2 (ja) | 二重特異性抗体及びその使用 | |
| JP6779012B2 (ja) | ブラジキニンｂ１受容体リガンドに対する抗体 | |
| JP2019527194A5 (enExample) | ||
| TW201641516A (zh) | 抗-ｉｌ-２３抗體 | |
| JP2017536354A (ja) | 抗プロ／潜在型−ミオスタチン抗体およびその使用 | |
| JP2019502405A (ja) | グリコシル化ｂｔｌａ（ｂ−及びｔ−リンパ球減弱因子）に特異的な抗体 | |
| TW201406391A (zh) | 抗－ｉｌ－２３抗體 | |
| JP2020527152A5 (enExample) | ||
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| JP2021506325A (ja) | Ｃｄ２２に結合する重鎖抗体 | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2013508292A5 (enExample) | ||
| EP3454901A1 (en) | Compositions and methods for treating spinal muscular atrophy | |
| DE112019003835T5 (de) | Arzneimittel zur verwendung bei der behandlung oder vorbeugung einer mit c5 in zusammenhang stehenden erkrankung sowie verfahren zur behandlung oder vorbeugung einer mit c5 in zusammenhang stehenden erkrankung | |
| US20240101674A1 (en) | Pd1 and vegfr2 dual-binding agents | |
| EP3487531A1 (en) | Compositions and methods for treating frontotemporal dementia | |
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| WO2019169015A1 (en) | Anti cd6 antibodies for treating severe asthma | |
| JP2023545075A (ja) | ＣＤ１ａ抗体およびその使用 |